SB-431542

SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) . SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways[1][2][3].

Product Specifications

CAS Number

[301836-41-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Organoid; TGF-β Receptor

Type

Reference compound

Related Pathways

Apoptosis; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SB-431542.html

Purity

99.85

Solubility

DMSO : 50 mg/mL (ultrasonic) |Ethanol : 11.17 mg/mL (ultrasonic; warming)

Smiles

O=C(C1=CC=C(C=C1)C2=NC(C3=CC=C4OCOC4=C3)=C(N2)C5=NC=CC=C5)N

Molecular Formula

C22H16N4O3

Molecular Weight

384.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Gareth J Inman, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002 Jul;62 (1) :65-74.|[2]Sunil K Halder, et al. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005 May;7 (5) :509-21.|[3]Yi-qin Xiao, et al. SB-431542 inhibition of scar formation after filtration surgery and its potential mechanism. Invest Ophthalmol Vis Sci. 2009 Apr;50 (4) :1698-706.